Click here to join


Research on LAG-3 Technology.

  • Atkinson V, Khattak A, Haydon A, Eastgate M, Roy A, Prithviraj P, Mueller C, Brignone C, Triebel F. Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma. J lmmunother Cancer. 2020 Nov; 8(2):e001681.

  • Angin M, Brignone C, Triebel F. A LAG-3-Specific Agonist Antibody for the Treatment of T Cell-Induced Autoimmune Diseases. J lmmunol. 2020 Feb 15; 204(4):810-818.

  • Duhoux FP, Jager A, Dirix L, Huizing MT, Jerusalem G, Vuylsteke P, De Cuypere E, Breiner D, Mueller, Brignone C and Triebel F. 2017. Combination of paclitaxel and LAG-3lg (IMP321), a novel MHC class II agonist, as a first-line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): interim results from the run-in phase of a placebo controlled randomized phase II. Journal of Clinical Oncology 35:1062. 

  • Anderson, A. C., Joller, N. and Kuchroo, V. K.. 2016. Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. Immunity 44:5. 

  • Pardoll D. and Drake C.. 2012. Immunotherapy earns its spot in the ranks of cancer therapy. J Exp Med 209:2. 

  • Brignone, C., M. Gutierrez, F. Mefti, E. Brain, R. Jarcau, F. Cvitkovic, N. Bousetta, J. Medioni, J. Gligorov, C. Grygar, M. Marcu, and F. Triebel. 2010. First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. J Transl Med 8:71.

  • Brignone, C., B. Escudier, C. Grygar, M. Marcu, and F. Triebel. 2009. A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin Cancer Res 15:6225.

  • Brignone, C., C. Grygar, M. Marcu, K. Schakel, and F. Triebel. 2007. A soluble form of lymphocyte activation gene-3 (IMP321) induces activation of a large range of human effector cytotoxic cells. J Immunol 179:4202.

  • Triebel, F., K. Hacene, and M. F. Pichon. 2006. A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors. Cancer Lett 235:147.

  • Triebel, F. 2003. LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination. Trends Immunol 24:619.

  • Prigent, P., S. E. Mir, M. Dreano, and F. Triebel. 1999. LAG-3 induces tumor regression and antitumor immune responses in vivo. Eur. J. Immunol. 29:3867.

  • Huard, B., R. Mastrangeli, P. Prigent, D. Bruniquel, S. Donini, N. El-Tayar, B. Maigret, M. Dreano, and F. Triebel. 1997. Characterization of the major histocompatibility complex class II binding site on LAG-3 protein. Proc. Natl. Acad. Sci. USA 94:5744.

  • Triebel, F., S. Jitsukawa, E. Baixeras, S. Roman-Roman, C. Genevée, E. Viegas-Pequignot, and T. Hercend. 1990. LAG-3, a novel lymphocyte activation gene closely related to CD4. J.Exp. Med. 171:1393.